# Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

> **NCT06111768** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yale University** · enrollment: 30 (actual)

## Conditions studied

- Cardiorenal Syndrome

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT06111768
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06111768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06111768, "Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06111768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*